Related Experiment Video
Updated: Mar 17, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Downregulation of coding transmembrane protein 35 gene inhibits cell proliferation, migration and cell cycle arrest
Yinjun Huang1, Shichang Zhao1, Yadong Zhang1
1Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
Abstract:
Osteosarcoma (OSA) is the most common primary tumor of the bone. Resistance to chemotherapy and the fast rapid development of metastatic lesions are major issues responsible for treatment failure and poor survival rates in OSA patients. Tetraspanins comprise a family of transmembrane receptor glycoproteins that affect tumor cell migration through tetraspanin-integrin interaction. The present study focused on a four-pass transmembrane protein gene, transmembrane protein 35 (TMEM35) gene, and examined its role in the growth, migration and cell cycle progression of OSA cells. In addition, the study discussed whether the TMEM35 gene, which encodes the TMEM35 protein, may be a potential therapeutic target for OSA. In the current study, reverse transcription-quantitative polymerase chain reaction was performed to examine TMEM35 expression in OSA and matched healthy tissues. Small interfering RNAs (siRNAs) were transfected into SaOS2 and U2OS cells to knockdown the TMEM35 expression. Soft-agar colony formation assay was performed to evaluate cell growth, and cell cycle progression was analyzed by flow cytometry. Wound-healing and Boyden chamber assays were also performed to investigate cell invasion and migration by the SaOS2 and U2OS cells. TMEM35 protein was analyzed in a functional protein interaction networks database (STRING database) to predict the functional interaction partner proteins of TMEM35. The results indicated that TMEM35 was abnormally expressed in OSA tissues. Of the 37 examined patients, TMEM35 expression was significantly increased in the OSA tissues of 24 patients (64.86%; P<0.05), when compared with the expression in normal tissues. Furthermore, TMEM35 knockdown following transfection with siRNAs inhibited the colony formation ability of SaOS2 and U2OS cells in soft agar. Flow cytometric analysis also revealed that TMEM35 knockdown by RNA interference may result in G1 phase arrest and a decreased cell population at the S phase. TMEM35 knockdown inhibited cell migration in SaOS2 and U2OS cells in wound-healing assays. In conclusion, TMEM35, a member of the tetraspanin family, serves an important role in the growth of OSA cells.
Insights
Transmembrane protein 35 (TMEM35) is overexpressed in osteosarcoma (OSA) and drives tumor growth and migration. Inhibiting TMEM35 may offer a new therapeutic strategy for this bone cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma (OSA) is the most common primary bone tumor, characterized by poor survival rates due to chemotherapy resistance and metastasis.
- Tetraspanins, including transmembrane protein 35 (TMEM35), are implicated in cancer cell migration via tetraspanin-integrin interactions.
- The role of TMEM35 in OSA progression and its potential as a therapeutic target remain underexplored.
Purpose of the Study:
- To investigate the role of the transmembrane protein 35 (TMEM35) gene in osteosarcoma (OSA) cell growth, migration, and cell cycle progression.
- To evaluate TMEM35 as a potential therapeutic target for OSA treatment.
Main Methods:
- Quantitative reverse transcription polymerase chain reaction (RT-qPCR) to assess TMEM35 expression in OSA tissues versus normal tissues.
- Small interfering RNA (siRNA)-mediated knockdown of TMEM35 in SaOS2 and U2OS OSA cell lines.
- Assays including soft-agar colony formation, flow cytometry (cell cycle analysis), wound-healing, and Boyden chamber assays to evaluate cellular functions.
Main Results:
- TMEM35 was found to be abnormally expressed and significantly upregulated in a majority of OSA tissues compared to matched healthy tissues.
- Knockdown of TMEM35 expression using siRNAs significantly inhibited OSA cell proliferation (colony formation) and induced G1 phase arrest.
- TMEM35 knockdown also markedly reduced the invasive and migratory capabilities of OSA cells in vitro.
Conclusions:
- TMEM35 plays a critical role in the proliferation and migration of osteosarcoma cells.
- The findings suggest that TMEM35 is a potential therapeutic target for combating osteosarcoma progression and metastasis.
More Related Videos
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
Abnormal Proliferation
Replicative Cell Senescence
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Mitogens and the Cell Cycle